194 related articles for article (PubMed ID: 30546958)
1. Immunoprofiles of colorectal cancer from Lynch syndrome.
Walkowska J; Kallemose T; Jönsson G; Jönsson M; Andersen O; Andersen MH; Svane IM; Langkilde A; Nilbert M; Therkildsen C
Oncoimmunology; 2019; 8(1):e1515612. PubMed ID: 30546958
[TBL] [Abstract][Full Text] [Related]
2. Lynch syndrome-associated epithelial ovarian cancer and its immunological profile.
Rasmussen M; Lim K; Rambech E; Andersen MH; Svane IM; Andersen O; Jensen LH; Nilbert M; Therkildsen C
Gynecol Oncol; 2021 Sep; 162(3):686-693. PubMed ID: 34275654
[TBL] [Abstract][Full Text] [Related]
3. Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.
Echterdiek F; Janikovits J; Staffa L; Müller M; Lahrmann B; Frühschütz M; Hartog B; Nelius N; Benner A; Tariverdian M; von Knebel Doeberitz M; Grabe N; Kloor M
Oncoimmunology; 2016 Feb; 5(2):e1075692. PubMed ID: 27057447
[TBL] [Abstract][Full Text] [Related]
4. High numbers of PDCD1 (PD-1)-positive T cells and
Janikovits J; Müller M; Krzykalla J; Körner S; Echterdiek F; Lahrmann B; Grabe N; Schneider M; Benner A; Doeberitz MVK; Kloor M
Oncoimmunology; 2018; 7(2):e1390640. PubMed ID: 29308317
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
[TBL] [Abstract][Full Text] [Related]
6. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.
Ramchander NC; Ryan NAJ; Walker TDJ; Harries L; Bolton J; Bosse T; Evans DG; Crosbie EJ
Front Immunol; 2019; 10():3023. PubMed ID: 31998307
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
8. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
Carethers JM; Stoffel EM
World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
[TBL] [Abstract][Full Text] [Related]
9. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
10. Hereditary non-polyposis colorectal cancer/Lynch syndrome in three dimensions.
Kravochuck SE; Church JM
ANZ J Surg; 2017 Dec; 87(12):1006-1010. PubMed ID: 26990828
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability.
Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y
Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503
[TBL] [Abstract][Full Text] [Related]
12. The Clinical and Biomarker Association of Programmed Death Ligand 1 and its Spatial Heterogeneous Expression in Colorectal Cancer.
Wei XL; Wu QN; Chen DL; Zeng ZL; Lu JB; Liu ZX; Ju HQ; Ren C; Pan ZZ; Wang FH; Xu RH
J Cancer; 2018; 9(23):4325-4333. PubMed ID: 30519336
[No Abstract] [Full Text] [Related]
13. Somatic mutations of the coding microsatellites within the beta-2-microglobulin gene in mismatch repair-deficient colorectal cancers and adenomas.
Clendenning M; Huang A; Jayasekara H; Lorans M; Preston S; O'Callaghan N; Pope BJ; Macrae FA; Winship IM; Milne RL; Giles GG; English DR; Hopper JL; Win AK; Jenkins MA; Southey MC; Rosty C; Buchanan DD;
Fam Cancer; 2018 Jan; 17(1):91-100. PubMed ID: 28616688
[TBL] [Abstract][Full Text] [Related]
14. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Lynch syndrome among patients with upper urinary tract carcinoma in a Japanese hospital-based population.
Ito T; Kono K; Eguchi H; Okazaki Y; Yamamoto G; Tachikawa T; Akagi K; Okada Y; Kawakami S; Morozumi M; Tamaru JI; Ishida H
Jpn J Clin Oncol; 2020 Jan; 50(1):80-88. PubMed ID: 31665498
[TBL] [Abstract][Full Text] [Related]
16. Recent discoveries in the molecular genetics of Lynch syndrome.
Boland CR
Fam Cancer; 2016 Jul; 15(3):395-403. PubMed ID: 27038793
[TBL] [Abstract][Full Text] [Related]
17. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
18. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome.
Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M
Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427
[TBL] [Abstract][Full Text] [Related]
19. Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.
Chang K; Taggart MW; Reyes-Uribe L; Borras E; Riquelme E; Barnett RM; Leoni G; San Lucas FA; Catanese MT; Mori F; Diodoro MG; You YN; Hawk ET; Roszik J; Scheet P; Kopetz S; Nicosia A; Scarselli E; Lynch PM; McAllister F; Vilar E
JAMA Oncol; 2018 Aug; 4(8):1085-1092. PubMed ID: 29710228
[TBL] [Abstract][Full Text] [Related]
20. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
